This panel will review the deals from 2025 to draw learnings for 2026. We will discuss how to approach pharma when preparing a deal. Our discussion will also cover geopolitical aspects such as tariffs and MFN, and how they could influence deals.
Our panel includes:
- Marc de Garidel, CEO at Abivax.
- Eric Tokat, Co-President & Partner at Centerview Partners.
- Caroline Boulliat, CEO at Genchrome and former pharma executive at Amgen, Pfizer, MSD, and GSK.
Eric Tokat is a founder of Centerview’s Healthcare practice and has advised on 100+ transactions representing more than $500bn in value, helping establish Centerview as a reference in strategic healthcare advisory.
Marc de Garidel leads one of the most closely watched biotech stories of 2025. Following positive Phase 3 data for obefazimod in ulcerative colitis, Abivax has moved from sub-$500m valuation to over $8bn. Prior to Abivax, Marc successfully exited Corvidia Therapeutics to Novo Nordisk ($2.1bn) and CinCor Pharma, Inc. to AstraZeneca ($1.8bn), and currently serves as Chairman of Ipsen.
We look forward to your participation!
